Johnson & Johnson - JNJ STOCK NEWS

On December 5, 2021, Johnson & Johnson (NYSE: JNJ) announced preliminary findings from a study indicating that a booster shot of its COVID-19 vaccine, Ad26.COV2.S, significantly enhances antibody and T-cell responses when administered six months post a two-dose regimen of BNT162b2. Conducted by Dan Barouch, M.D., Ph.D., the study suggests a mix-and-match approach could yield superior immune responses. Results also align with previous UK studies showcasing increased immunogenicity with Johnson & Johnson's vaccine. The CDC recommends this booster for all eligible individuals.

Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will present data from six studies on its respiratory syncytial virus (RSV) vaccine candidate at the Eighth European Scientific Working Group on Influenza meeting. Highlights include findings from the Phase 2b CYPRESS trial, showing 80% effectiveness against lower respiratory infections. The vaccine candidate has received Breakthrough Therapy Designation from the FDA and is currently in Phase 3 trials. The urgent need for an RSV vaccine remains, as no effective treatments exist for older adults at high risk.

Johnson & Johnson (NYSE: JNJ) announced plans to spin off its Consumer Health business, creating two independent companies. The split aims to enhance focus, agility, and innovation in healthcare, positioning the new Johnson & Johnson as a leader in pharmaceuticals and medical devices, projected to generate $77 billion in revenue for FY 2021. The New Consumer Health Company will be a global leader in health products with $15 billion projected revenue. The separation is expected to be tax-free for U.S. federal purposes and is targeted for completion within 18-24 months, pending regulatory approvals.

Johnson & Johnson (NYSE: JNJ) announced a partnership with the U.S. Government and Gavi to distribute its single-shot COVID-19 vaccine via the COVAX Humanitarian Buffer. This initiative aims to reach vulnerable populations in conflict zones and areas lacking government vaccination campaigns. The first vaccine deliveries are set for the coming days. The company plans to supply up to 900 million doses on a not-for-profit basis, highlighting its commitment to equitable global access in the fight against the pandemic.

Johnson & Johnson (NYSE: JNJ) has announced a $5 million endowment to Research!America to establish an annual award aimed at recognizing significant contributions to public health. This award will be part of the 26th annual Research!America Advocacy Awards Program. The initiative highlights leaders tackling key health issues like smoking cessation and COVID-19 collaboration. Notable awardees include Matthew Myers, Bill Novelli, and Vivian W. Pinn, MD, who have made significant impacts in public health. The company emphasizes its commitment to advancing global health.

On October 21, 2021, Johnson & Johnson (NYSE: JNJ) announced that the CDC's Advisory Committee on Immunization Practices recommended its COVID-19 vaccine as a booster for individuals who have received authorized COVID-19 vaccines. The vaccine demonstrated 94% protection against COVID-19 as a booster, emphasizing its durable protection. The recommendations include boosters for adults aged 18 and older who either received the single-shot Johnson & Johnson vaccine or completed primary vaccination with an mRNA vaccine at least six months earlier. The recommendation is pending review by the CDC and HHS.

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the fourth quarter of 2021. This dividend will be paid on December 7, 2021, to shareholders recorded as of the close of business on November 23, 2021. The ex-dividend date is scheduled for November 22, 2021. With over 130 years in the healthcare industry, Johnson & Johnson remains committed to enhancing health and well-being globally.

Johnson & Johnson (NYSE: JNJ) received Emergency Use Authorization (EUA) from the FDA for its COVID-19 vaccine booster for adults aged 18 and older, effective two months after the initial vaccination. The booster dose will share the same formulation and dosage as the primary shot. The EUA is based on a favorable recommendation from the FDA's advisory committee, highlighting robust efficacy and safety data from clinical trials. Over 15.2 million doses of the vaccine have already been administered in the U.S., underscoring its significant role in combating the ongoing pandemic.

Johnson & Johnson (NYSE: JNJ) reported Q3 2021 results, showcasing a 10.7% increase in reported sales to $23.3 billion and a 3.2% rise in net earnings to $3.67 billion. Adjusted EPS surged 18.2% to $2.60. Pharmaceutical sales grew 13.8%, led by drugs like DARZALEX and STELARA. Medical Devices operations rose 7.6%, while Consumer Health increased 5.7%. CEO Alex Gorsky announced his transition to Joaquin Duato effective January 2022, underscoring ongoing investment in innovation amidst dynamic market conditions.